The use of macrolides for treatment of diffuse panbronchiolitis

2005 ◽  
pp. 147-165 ◽  
Author(s):  
Arata Azuma ◽  
Shoji Kudoh
Keyword(s):  
Diffuse Panbronchiolitis

Diffuse Panbronchiolitis bei einem deutschen Patienten – Verlauf über 11 Jahre bis zur Diagnose

Pneumologie ◽  
2005 ◽  
Vol 59 (S 1) ◽  
Author(s):  
M Held ◽  
I Bittmann ◽  
E Heckelsmüller ◽  
KM Müller
Keyword(s):  
Diffuse Panbronchiolitis

scholarly journals Isolation of Mycobacterium talmoniae from a patient with diffuse panbronchiolitis: a case report

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Tomoko Suzuki ◽  
Miwako Saitou ◽  
Yuriko Igarashi ◽  
Satoshi Mitarai ◽  
Katsunao Niitsuma
Keyword(s):  
Combination Therapy ◽  
Bronchoalveolar Lavage Fluid ◽  
Left Lung ◽  
Lavage Fluid ◽  
Drug Susceptibility ◽  
Acid Fast Bacillus ◽  
Case Presentation ◽  
Diffuse Panbronchiolitis ◽  
Potential Pathogen ◽  
Culture Positive

Abstract Background Mycobacterium (M) talmoniae isolated from a patient with cystic fibrosis was first described in 2017, and cases of M. talmoniae remain exceedingly rare. Case presentation A 51-year-old woman had respiratory symptoms for 10 years. Diffuse panbronchiolitis (DPB) was detected at the first visit at our hospital. A cavity lesion in the apex of the left lung was found, and sputum and bronchoalveolar lavage fluid were acid-fast bacillus (AFB) smear- and culture-positive besides Pseudomonas aeruginosa. M. talmoniae was finally identified, and the standard combination therapy for non-tuberculous mycobacteria (NTM) was administered for 2 y referring to the drug-susceptibility test. Thereafter, the AFB culture was negative, the wall thickness of the lung cavity was ameliorated, and oxygen saturation improved. Conclusions We encountered a rare case of M. talmoniae with DPB, for which standard combination therapy was effective. M. talmoniae may be considered a potential pathogen of lung disease, especially in patients with bronchiectatic lesions.

Ofloxacin and Macrolides in the Treatment of Diffuse Panbronchiolitis

Drugs ◽  
1993 ◽  
Vol 45 (Supplement 3) ◽  
pp. 401-402
Author(s):  
Osamu Tanabe ◽  
Katumi Komatuzaki ◽  
Hiroko Tada ◽  
Ayumu Shimizu ◽  
Taichi Mochizuki ◽  
...  
Keyword(s):  
Diffuse Panbronchiolitis

A case of diffuse panbronchiolitis

2000 ◽  
Vol 30 (1) ◽  
pp. 99-100 ◽  
Author(s):  
S. CLAXTON ◽  
J. MARKOS
Keyword(s):  
Diffuse Panbronchiolitis

A Study of Peripheral Airway Findings Using an Ultrathin Bronchofiberscope and Bronchoalveolar Lavage Fluid with Diffuse Panbronchiolitis

Respiration ◽  
1998 ◽  
Vol 65 (6) ◽  
pp. 433-440 ◽  
Author(s):  
Masayuki Kikawada ◽  
Yuichi Ichinose ◽  
Kazushige Minemura ◽  
Masaru Takasaki ◽  
Keisuke Toyama
Keyword(s):  
Bronchoalveolar Lavage ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Diffuse Panbronchiolitis ◽  
Peripheral Airway

scholarly journals Azithromycin treats diffuse panbronchiolitis by targeting T cells via inhibition of mTOR pathway

2019 ◽  
Vol 110 ◽  
pp. 440-448 ◽  
Author(s):  
Dong Weng ◽  
Qin Wu ◽  
Xian-Qiu Chen ◽  
Yu-Kui Du ◽  
Tao Chen ◽  
...  
Keyword(s):  
T Cells ◽  
Mtor Pathway ◽  
Diffuse Panbronchiolitis

Diffuse Panbronchiolitis

CHEST Journal ◽  
2002 ◽  
Vol 121 (2) ◽  
pp. 659-661 ◽  
Author(s):  
Padmanabhan Krishnan ◽  
Rajeeve Thachil ◽  
Virgilio Gillego
Keyword(s):  
Diffuse Panbronchiolitis

scholarly journals Erythromycin shortens neutrophil survival by accelerating apoptosis.

1995 ◽  
Vol 39 (4) ◽  
pp. 872-877 ◽  
Author(s):  
K Aoshiba ◽  
A Nagai ◽  
K Konno
Keyword(s):  
Inflammatory Diseases ◽  
Clinical Effectiveness ◽  
Maximum Effect ◽  
Intracellular Camp ◽  
Diffuse Panbronchiolitis ◽  
Dose Dependent Fashion ◽  
Anti Inflammatory ◽  
Neutrophil Survival ◽  
Camp Levels ◽  
Inflammatory Action

Erythromycin is reported to have an anti-inflammatory action, which may account for its clinical effectiveness in the treatment of chronic inflammatory diseases such as diffuse panbronchiolitis. To evaluate the anti-inflammatory action of erythromycin, we examined the survival of isolated neutrophils with and without erythromycin. Erythromycin shortened neutrophil survival in a dose-dependent fashion, with a maximum effect at 10 micrograms/ml [corrected] and above. Survival at 24 h was 63.4% in medium with 10 micrograms of erythromycin per ml compared with 82.7% in control medium (P < 0.01). This shortening of survival was brought about by acceleration of apoptosis, as evidenced by transmission electron microscopy. In a manner similar to that of erythromycin, other macrolide antibiotics, i.e., clarithromycin, roxithromycin, and midecamycin, also shortened neutrophil survival, but neither the beta-lactams ampicillin and cefazolin nor the aminoglycoside gentamicin affected their survival. Erythromycin increased intracellular levels of cyclic AMP (cAMP) to 150% of control levels in neutrophils. Forskolin, rolipram, and dibutyryl-cAMP, which are known to increase intracellular cAMP levels, also shortened neutrophil survival. H-89, an inhibitor of cAMP-dependent protein kinase A, partially blocked the survival-shortening effect of erythromycin. Our findings suggest that erythromycin shortens neutrophil survival at least in part through elevation of intracellular cAMP levels.

Diffuse panbronchiolitis: efficacy of low-dose erythromycin

1993 ◽  
Vol 87 (3) ◽  
pp. 229-230 ◽  
Author(s):  
J. Tredaniel ◽  
G. Zalcman ◽  
F. Gerber ◽  
M.F. D'Agay ◽  
F. Capron ◽  
...  
Keyword(s):  
Low Dose ◽  
Diffuse Panbronchiolitis
Sign in / Sign up

Export Citation Format

Share Document